GLP-1 Injection Frequency: Weekly & Personalized Dosing

Last reviewed: May 21, 2026

Last updated: May 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Most GLP-1 receptor agonist injections are administered once weekly via subcutaneous injection. This frequency applies to semaglutide, tirzepatide, and other common compounds. Some newer agents permit less frequent dosing—for example, retatrutide and certain long-acting formulations may allow biweekly or monthly administration.

Understanding injection frequency matters because it affects treatment adherence, real-world effectiveness, and side effect management. PlexusDx positions this conversation within a precision-wellness framework: your genetic background and biomarker profile can inform how you tolerate dosing schedules and titration protocols, helping providers customize your treatment plan.

Standard Weekly Injection Schedules for Common GLP-1 Agents

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are prescribed as once-weekly subcutaneous injections. Patients typically start at a low dose and titrate upward every 4 weeks over 16–20 weeks to reach therapeutic dosing. This gradual escalation reduces gastrointestinal side effects and improves tolerability.

Weekly injection timing offers a predictable rhythm that many patients find easier to remember than daily medications. Patients select one day per week—often Monday or Friday—and inject at the same time each week. This consistency supports medication adherence and allows providers to monitor response and side effects over a standardized timeline.

GLP-1 Dosing Frequency and Titration Protocols Across Medications

Different GLP-1 compounds follow distinct titration schedules. Semaglutide titration typically spans 16 weeks with four dose escalations. Tirzepatide follows a similar 16-week escalation with four steps. Retatrutide, a newer triple agonist, may allow biweekly or monthly dosing in some protocols, though most GLP-1s remain weekly.

Medication	Standard Frequency	Titration Duration	Typical Max Dose
Semaglutide	Once weekly	16 weeks (4 steps)	2.4 mg/week
Tirzepatide	Once weekly	16 weeks (4 steps)	15 mg/week
Retatrutide	Once weekly or biweekly	Up to 20 weeks	15 mg/week
Liraglutide	Daily injection	Variable	3.0 mg/day

Dose Escalation Timing and Tolerability Adjustments

Standard protocol advances dosing every 4 weeks, allowing the body to adapt. However, some patients experience persistent nausea, vomiting, or constipation and benefit from extended intervals between dose increases—5 or 6 weeks rather than 4. Providers may pause at intermediate doses or slow titration based on clinical response and reported side effects.

Genetic variants in GLP1R, GIPR, and FTO pathways may influence how quickly a patient's metabolism adapts to dose escalation. Those with certain variants may tolerate faster titration, while others benefit from extended intervals. Biomarker assessment can provide clinical context for personalizing your dosing timeline with your provider.

Who Benefits from Standard Weekly Dosing and When Alternatives May Apply

Weekly injection schedules work well for most patients with type 2 diabetes or weight-management goals who tolerate the standard titration. Patients with stable kidney function, no contraindicated comorbidities, and adequate injection confidence are ideal candidates. Those with a history of pancreatitis, severe gastroparesis, or active thyroid disease require provider evaluation before starting.

Less frequent dosing (biweekly or monthly) may become available as newer compounds advance. Currently, most GLP-1 therapy in clinical practice remains weekly. Your healthcare provider will confirm the appropriate frequency based on your diagnosis, comorbidities, renal function, and tolerability profile. A qualified assessment—potentially including biomarker and genetic context—informs this decision.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your genetic predispositions in peptide pathways, including GLP1R, GIPR, FTO, and MC4R variants. These genetic markers reveal inherited differences in how your body responds to GLP-1 compounds and how quickly you may tolerate dose escalation. This information should be interpreted with a qualified healthcare provider to support a more personalized dosing conversation.

The test does not predict your exact medication response or guarantee how quickly you will reach therapeutic doses. Rather, it identifies genetic predispositions that may influence tolerability and efficacy trends. For example, certain GLP1R variants correlate with differential appetite suppression response, while FTO variants may relate to baseline metabolic risk. Understanding these pathways can inform provider discussions about titration speed and dose-adjustment expectations.

When combined with clinical biomarkers—such as HbA1c, fasting glucose, kidney function, and inflammatory markers—genetic insights support a more informed conversation with your provider about whether standard weekly dosing and typical 4-week titration intervals align with your physiology, or whether adjustments may be warranted. This precision approach helps move beyond one-size-fits-all protocols toward individualized treatment planning.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.